• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Stephen K. Williamson, James Moon, +4 authors Susan G. Urba
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2010 (First Publication: 10 July 2010)
  • PURPOSE We conducted a phase II trial to evaluate the efficacy and safety of single-agent sorafenib in chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the head andContinue Reading
  • Primo N. Lara, Kari Chansky, +8 authors David R Gandara
  • Medicine
  • Journal of thoracic oncology : official…
  • 2006 (First Publication: 1 November 2006)
  • BACKGROUND In preclinical models, the proteasome inhibitor bortezomib (PS-341) inhibits the growth of small cell lung cancer (SCLC) by inhibiting the antiapoptotic Bcl-2 signaling pathway. WeContinue Reading
  • Charles A. Kunos, Wei Deng, +7 authors Kathleen N. Moore
  • Medicine
  • International journal of gynecological cancer…
  • 2015 (First Publication: 10 March 2015)
  • PURPOSE The aim of this study was to evaluate the tolerability and efficacy of poly(ADP-ribose) polymerase (PARP) inhibition by veliparib during cytotoxic topotecan administration with filgrastim orContinue Reading
  • Roy S. Herbst, Mary W. Redman, +15 authors David R Gandara
  • Medicine
  • The Lancet. Oncology
  • 2018
  • BACKGROUND EGFR antibodies have shown promise in patients with advanced non-small-cell lung cancer (NSCLC), particularly with squamous cell histology. We hypothesised that EGFR copy number byContinue Reading
  • Stephen K. Williamson, James B Moon, Chao H. Huang, Perry P Guaglianone, Gregory T. Wolf, Susan G. Urba
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2006
  • 5550 Background: Bay 43-9006 (Sorafenib) is a potent Raf-1 and B-Raf kinase inhibitor of the RAS/RAF/MEK/ERK pathway. The compound also inhibits protein tyrosine kinases associated with VEGFR-2 and 3Continue Reading
  • Fred R Hirsch, Mary W. Redman, +15 authors David R Gandara
  • Medicine
  • 2016 (First Publication: 20 May 2016)
  • 9090Background: The SWOG 0819 study compared chemotherapy (CT) (+/- bevacizumab) to CT combined with cetuximab and included 1,313 eligible patients (pts) of which 321 had squamous histology (SCC). ...
  • Stephen K. Williamson, James Moon, Chao H. Huang, Perry P Guaglianone, Gregory T. Wolf, Susan G. Urba
  • Medicine
  • 2016 (First Publication: 12 December 2016)
  • 5550 Background: Bay 43–9006 (Sorafenib) is a potent Raf-1 and B-Raf kinase inhibitor of the RAS/RAF/MEK/ERK pathway. The compound also inhibits protein tyrosine kinases associated with VEGFR-2 and 3Continue Reading
  • Jill M Kolesar, J. Brahmer, +7 authors Joan H. Schiller
  • Medicine
  • 2007 (First Publication: 20 June 2007)
  • 7162 Background: Markers of response and survival in patients (pts) who benefit from erlotinib (Elb) remain controversial. In another study, pts who developed a rash on Elb survived longer. The pri...
  • Jill M Kolesar, Julie R. Brahmer, +7 authors Joan H. Schiller
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2006
  • 7162 Background: Markers of response and survival in patients (pts) who benefit from erlotinib (Elb) remain controversial. In another study, pts who developed a rash on Elb survived longer. TheContinue Reading